An interventional study of Serranator PTA Serration Catheter and PTA (Standard of Care) in Critical Limb Ischemia, sponsored by Cagent Vascular LLC. Recruiting at 2 sites in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-05-18.
Sponsored by Cagent Vascular LLC · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States — 13 open to participants now, 20 under way, 2 of them phase 3. Chronic Limb-Threatening Ischemia · United States.
Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, this one is the 31st largest by planned enrollment of the 82 interventional ones that give a count, is one of 6 that started in 2024, is one of 38 with no phase, reaches primary completion later than 4 of the 19 other live ones, and was the 101st registered.
359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.
Browse Chronic Limb-Threatening Ischemia studies →13 of the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States are open now. Recruiting first, the newest first:
Mercator MedSystems, Inc. · Sites in United States
Ages 18+
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–99
R3 Vascular Inc. · Sites in United States
Ages 18+
Medistim ASA · Sites in United States
Ages 18+
Versono Medical Ltd · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 19 · Phase 3 10 · Phase 4 3
First in 2003; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 41 across 240 interventional studies indexed under Chronic Limb-Threatening Ischemia.
Median enrollment 38 across the 82 interventional studies, 102 across the 19 observational. Of the 69 that completed or were terminated, 25 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 105 have an industry lead sponsor. The 10 most frequent:
Cagent Vascular LLC is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Cagent Vascular LLC has 3 studies filed under Chronic Limb-Threatening Ischemia — fewer than ten, so there is no comparison to draw.
9 of the studies in Chronic Limb-Threatening Ischemia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03982693Phase 3Mt. Sinai Medical Center, MiamiTrial to Assess Chelation Therapy in Critical Limb Ischemia | 2026-12 |
| NCT06492733Versono Medical LtdFastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW | 2026-11 |
| NCT05830721Johns Hopkins UniversityContinuous Compartment Pressure Monitoring for Compartment Syndrome in VA-ECMO Patients | 2026-12 |
| NCT05145478Yale UniversityCRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions | 2026-12-31 |
| NCT06311773Aveera Medical, Inc.Pivotal Trial of the Boomerang Catheter for pDVA | 2027-03-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
TA prospective randomized control trial to evaluate the serration angioplasty effect in BTK arteries with varying degrees of calcified plaque.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to the Serranator Arm of the study will be treated with the Serranator PTA Serration Balloon
Device: Serranator PTA Serration Catheter
Subjects randomized to the PTA Arm of the study will be treated with a standard of care percutaneous transluminal angioplasty (PTA) balloon.
Drug: PTA (Standard of Care)
The Serranator PTA Serration Balloon Catheter is an over-the-wire balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
A percutaneous transluminal angioplasty catheter will be used to treat the target lesion.
Residual Lumen Volume Stenosis
Residual lumen volume stenosis derived by OCT comparing Serration Angioplasty and conventional plain balloon angioplasty (PTA) measured at 10-15min post procedure. The lesion segment is defined as the entire treated segment where the balloon has been inflated.
Time frame: Baseline
OCT Residual Diameter Stenosis
Residual stenosis as measured by OCT
Time frame: Baseline
Angiography Residual Diameter Stenosis
Residual stenosis as measured by angiography
Time frame: Baseline
Dissection Pattern
The incidence of dissection pattern between the study arms as reported by the OCT Corelab. The CoreLab will evaluate OCT images of each dissection including analysis of the length of the dissection, arc of the dissection, number of serrations, and the length of the serration.
Time frame: Baseline
Correlation of Luminal Gain and Plaque Modification
The correlation of the plaque modification achieved as determine from the OCT evaluation after treatment with the Study Device to the luminal gain achieved by conventional angioplasty as evaluated by the Core Lab.
Time frame: Baseline
Rate of Optimal PTA
Rate of procedures that achieve optimal PTA (\<30% diameter stenosis without flow-limiting dissection measured by angiography)
Time frame: Baseline
Bail-out Stenting
Rate of bail-out stenting
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Jun 2025, 7 months after the start.
Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 7 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chronic Limb-Threatening Ischemia →
Cagent Vascular LLC